Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Running, not enrolling

Conditions studied: Melanoma; Renal Cell Carcinoma

In brief

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Key facts

Study ID

NCT03728842

Run by

Indiana University

People needed

19

Starts

2004-01-04

Expected to finish

2027-03-01

Last updated by the study team

2025-10-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old at the time of informed consent
• Ability to provide written informed consent and HIPAA authorization
• Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
• Willingness to undergo phlebotomy for research blood samples

You may not qualify if…

• Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety
• Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Where it is running

• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.